Outcomes of single- and two-stage revision total knee arthroplasty for chronic periprosthetic joint infection

医学 假体周围 生存曲线 外科 队列 关节置换术 比例危险模型 内科学 回顾性队列研究 阶段(地层学) 癌症 生物 古生物学
作者
Hosam E. Matar,Benjamin V. Bloch,S. Snape,Peter James
出处
期刊:The bone & joint journal [British Editorial Society of Bone & Joint Surgery]
卷期号:103-B (8): 1373-1379 被引量:41
标识
DOI:10.1302/0301-620x.103b8.bjj-2021-0224.r1
摘要

Aims Single-stage revision total knee arthroplasty (rTKA) is gaining popularity in treating chronic periprosthetic joint infections (PJIs). We have introduced this approach to our clinical practice and sought to evaluate rates of reinfection and re-revision, along with predictors of failure of both single- and two-stage rTKA for chronic PJI. Methods A retrospective comparative cohort study of all rTKAs for chronic PJI between 1 April 2003 and 31 December 2018 was undertaken using prospective databases. Patients with acute infections were excluded; rTKAs were classified as single-stage, stage 1, or stage 2 of two-stage revision. The primary outcome measure was failure to eradicate or recurrent infection. Variables evaluated for failure by regression analysis included age, BMI, American Society of Anesthesiologists grade, infecting organisms, and the presence of a sinus. Patient survivorship was also compared between the groups. Results A total of 292 consecutive first-time rTKAs for chronic PJI were included: 82 single-stage (28.1%); and 210 two-stage (71.9%) revisions. The mean age was 71 years (27 to 90), with 165 females (57.4%), and a mean BMI of 30.9 kg/m 2 (20 to 53). Significantly more patients with a known infecting organism were in the single-stage group (93.9% vs 80.47%; p = 0.004). The infecting organism was identified preoperatively in 246 cases (84.2%). At a mean follow-up of 6.3 years (2.0 to 17.6), the failure rate was 6.1% in the single-stage, and 12% in the two-stage groups. All failures occurred within four years of treatment. The presence of a sinus was an independent risk factor for failure (odds ratio (OR) 4.97; 95% confidence interval (CI) 1.593 to 15.505; p = 0.006), as well as age > 80 years (OR 5.962; 95% CI 1.156 to 30.73; p = 0.033). The ten-year patient survivorship rate was 72% in the single-stage group compared with 70.5% in the two-stage group. This difference was not significant (p = 0.517). Conclusion Single-stage rTKA is an effective strategy with a high success rate comparable to two-stage approach in appropriately selected patients. Cite this article: Bone Joint J 2021;103-B(8):1373–1379.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
慕青应助傲娇的寄真采纳,获得10
刚刚
yangchang发布了新的文献求助10
刚刚
打打应助个性的荆采纳,获得10
刚刚
西陆完成签到,获得积分10
刚刚
zhuling完成签到,获得积分10
1秒前
大个应助研友_nPbeR8采纳,获得10
1秒前
开心友儿完成签到,获得积分10
2秒前
没所谓发布了新的文献求助10
2秒前
bkagyin应助笨蛋偷学采纳,获得10
2秒前
Yinzixin发布了新的文献求助10
2秒前
2秒前
机智瑛发布了新的文献求助10
3秒前
Hello应助zhuling采纳,获得10
3秒前
科研通AI2S应助冷静橘子采纳,获得10
4秒前
4秒前
4秒前
华仔应助Max哈哈哈采纳,获得10
5秒前
6秒前
6秒前
Lucas应助科研通管家采纳,获得10
6秒前
orixero应助科研通管家采纳,获得10
6秒前
桐桐应助科研通管家采纳,获得10
6秒前
ding应助科研通管家采纳,获得10
6秒前
大个应助科研通管家采纳,获得10
6秒前
CipherSage应助科研通管家采纳,获得10
6秒前
激动的项链完成签到,获得积分10
6秒前
pluto应助科研通管家采纳,获得10
6秒前
英俊的铭应助科研通管家采纳,获得10
6秒前
完美世界应助科研通管家采纳,获得30
6秒前
木柟应助科研通管家采纳,获得10
6秒前
英姑应助科研通管家采纳,获得10
6秒前
搜集达人应助科研通管家采纳,获得10
7秒前
王彤应助科研通管家采纳,获得10
7秒前
pluto应助科研通管家采纳,获得10
7秒前
BowieHuang应助科研通管家采纳,获得10
7秒前
7秒前
LOOK应助科研通管家采纳,获得20
7秒前
Untitled应助科研通管家采纳,获得20
7秒前
7秒前
Jasper应助科研通管家采纳,获得10
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Kinesiophobia : a new view of chronic pain behavior 2000
Cronologia da história de Macau 1600
Earth System Geophysics 1000
Bioseparations Science and Engineering Third Edition 1000
Lloyd's Register of Shipping's Approach to the Control of Incidents of Brittle Fracture in Ship Structures 1000
BRITTLE FRACTURE IN WELDED SHIPS 1000
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 纳米技术 有机化学 物理 生物化学 化学工程 计算机科学 复合材料 内科学 催化作用 光电子学 物理化学 电极 冶金 遗传学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 6126974
求助须知:如何正确求助?哪些是违规求助? 7954801
关于积分的说明 16505551
捐赠科研通 5246250
什么是DOI,文献DOI怎么找? 2801996
邀请新用户注册赠送积分活动 1783301
关于科研通互助平台的介绍 1654413